Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies

被引：0
|
作者：
Park, Yeon Hee
Cortes, Javier
Modi, Shanu
Hurvitz, Sara A.
Bianchini, Giampaolo
Iwata, Hiroji
Shitara, Kohei
Siena, Salvatore
Goto, Yasushi
Ku, Geoffrey Yuyat
Charles, Powell Andrew
Swain, Sandra M.
Arunachalam, Meena
Janek, Martin
Cheng, Yingkai
Chu, Changan
Verma, Purnima
Mathias, Elton
Karnoub, Maha
Rugo, Hope S.
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Quironsalud Grp, IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] Fred Hutchinson Canc Ctr, Seattle, WA USA
[6] Univ Vita Salute San Raffaele, Milan, Italy
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[9] Univ Milan, Milan, Italy
[10] Niguarda Canc Ctr, Milan, Italy
[11] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[12] Tisch Canc Inst, Mt Sinai Hosp, New York, NY USA
[13] Georgetown Univ, Washington, DC USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12118
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
    Epaillard, N.
    Lusque, A.
    Pistilli, B.
    Andre, F.
    Bachelot, T.
    Pierga, J-Y.
    Ducoulombier, A.
    Jouannaud, C.
    Viret, F.
    Salabert, L.
    Johnson, A. C.
    Deluche, E.
    Durando, X.
    Petit, T.
    Filleron, T.
    Oukhatar, C. Mahier Ait
    Dieras, V. C.
    Mosele, M. F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S656 - S656
  • [22] Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
    Joanne Wing Yan Chiu
    Soo Chin Lee
    James Chung-man Ho
    Yeon Hee Park
    Ta-Chung Chao
    Sung-Bae Kim
    Elgene Lim
    Ching-Hung Lin
    Sherene Loi
    Su Ying Low
    Lynette Li San Teo
    Winnie Yeo
    Rebecca Dent
    Drug Safety, 2023, 46 : 927 - 949
  • [23] HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors
    Takasugi, Nao
    Deguchi, Takao
    Kato, Motohiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)- related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management
    Swain, Sandra M.
    Nishino, Mizuki
    Lancaster, Lisa H.
    Li, Bob T.
    Nicholson, Andrew G.
    Bartholmai, Brian J.
    Naidoo, Jarushka
    Schumacher-Wulf, Eva
    Shitara, Kohei
    Tsurutani, Junji
    Conte, Pierfranco
    Kato, Terufumi
    Andre, Fabrice
    Powell, Charles A.
    CANCER TREATMENT REVIEWS, 2022, 106
  • [25] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
    Hsieh, Y. Pei
    ANNALS OF ONCOLOGY, 2024, 35 : S1394 - S1394
  • [26] EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Li, H.
    Wada, R.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S87 - S87
  • [27] Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
    Chiu, Joanne Wing Yan
    Lee, Soo Chin
    Ho, James Chung-man
    Park, Yeon Hee
    Chao, Ta-Chung
    Kim, Sung-Bae
    Lim, Elgene
    Lin, Ching-Hung
    Loi, Sherene
    Low, Su Ying
    Teo, Lynette Li San
    Yeo, Winnie
    Dent, Rebecca
    DRUG SAFETY, 2023, 46 (10) : 927 - 949
  • [28] Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
    Dieras, Veronique
    Deluche, Elise
    Lusque, Amelie
    Pistilli, Barbara
    Bachelot, Thomas
    Pierga, Jean-Yves
    Viret, Frederic
    Levy, Christelle
    Salabert, Laura
    Le Du, Fanny
    Dalenc, Florence
    Jouannaud, Christelle
    Venat-Bouvet, Laurence
    Jacquin, Jean-Philippe
    Durando, Xavier
    Petit, Thierry
    Oukhatar, Celine Mahier -Ait
    Filleron, Thomas
    Mosele, Maria Fernanda
    Lacroix-Triki, Magali
    Ducoulombier, Agnes
    Andre, Fabrice
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
    Andrikopoulou, Angeliki
    Zagouri, Flora
    Goula, Kallirroi
    Haidopoulos, Dimitrios
    Thomakos, Nikolaos
    Svarna, Anna
    Dimopoulos, Meletios-Athanasios
    Liontos, Michalis
    BMC CANCER, 2024, 24 (01)
  • [30] RELATE 2: A real-world observational study assessing feasibility, acceptability, perceived impacts of digital apps for patients receiving olaparib or trastuzumab deruxtecan (T-DXd) as part of routine clinical practice
    McGrath, Sophie
    Hall, Peter
    Acquadro, Michael
    Skovlund, Soren
    Jayia, Parveen
    McIntosh, Stuart
    Cameron, David
    CANCER RESEARCH, 2024, 84 (09)
12345